EMP-01

Small molecule

Phase 2topline reported

Evidence outlook

Social Anxiety Disorder: topline reported 2026-02-26

The sponsor reported topline results on 2026-02-26 (EMP-01 Phase 2a topline in social anxiety disorder (placebo-adjusted LSAS -11.85 at Day 43)). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Social Anxiety Disorder
Phase 1 (1)
Other / comorbidity
NCT06905652 · University Hospital, Basel, Switzerland
2025-07-29 – 2026-05-12 · Healthy
What this study did

Competitive landscape

This drug's own stage for Social Anxiety Disorder: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
EMP-01: this drugPhase 2Small moleculeSerotonergic system (MDMA-class entactogen)not yet gradedNo reviewed efficacy summary in this indication
FasedienolPhase 3Small moleculeNasal chemosensory receptorsPartial signal
NCT04754802: Subjective Units of Distress Scale (SUDS) Score (Visit 2 (Baseline; Day 0) to Visit 3 (Day 7 ± 2 days)): PH94B — Visit 2: 77.7 score on a scale (Standard Deviation 11.67); Visit 3: 62.3 score on a scale (Standard Deviation 19.4) | Placebo — Visit 2: 78.2 score on a scale (Standard Deviation 12.42); Visit 3: 61.3 score on a scale (Standard Deviation 19.56) missed

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 February 2026Topline resultEMP-01 Phase 2a topline in social anxiety disorder (placebo-adjusted LSAS -11.85 at Day 43)
US · AtaiBeckley Inc. · Source ↗